drugset / Trial / NCT06931080
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.
Timeline
- Start
- 2025-04-30
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Centanafadine | Small molecule | 164.4 mg | Oral |
| Subject | Centanafadine | Small molecule | 328.8 mg | Oral |